Table 4.
Estimation of the effectiveness of GIII live-attenuated JEV vaccine against GI and GIII viruses in gilts.
| Study Period | Circulating JEV Genotype | Vaccination Status of Gilt | Incidence (Abortion * or JEV(+) **) | Relative Ratio | Vaccine Effectiveness (%) | Reference |
|---|---|---|---|---|---|---|
| 2016–2017 | GI | Yes | 41/389 * | 0.345 (0.243–0.492) | 65.5 (50.8–75.7) | This study |
| No | 65/213 * | |||||
| Yes | 6/389 ** | 0.253 (0.098–0.655) | 74.7 (34.5–90.2) | This study | ||
| No | 13/213 ** | |||||
| 1969–1970 | GIII | Yes | 1/74 * | 0.044 (0.006–0.316) | 95.6 (68.3–99.4) | [15] |
* Incidence of stillbirth/abortion. ** Incidence of JEV-confirmed stillbirth/abortion.